UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Decreases Stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC decreased its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 10.0% in the 3rd quarter, HoldingsChannel reports. The fund owned 389,530 shares of the biotechnology company’s stock after selling 43,373 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in BioCryst Pharmaceuticals were worth $2,960,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. CWM LLC boosted its stake in shares of BioCryst Pharmaceuticals by 200.0% during the 2nd quarter. CWM LLC now owns 5,658 shares of the biotechnology company’s stock worth $35,000 after acquiring an additional 3,772 shares in the last quarter. Diversified Trust Co boosted its position in BioCryst Pharmaceuticals by 18.0% during the second quarter. Diversified Trust Co now owns 24,752 shares of the biotechnology company’s stock worth $153,000 after purchasing an additional 3,774 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in BioCryst Pharmaceuticals by 12.5% in the second quarter. Bank of New York Mellon Corp now owns 775,957 shares of the biotechnology company’s stock valued at $4,795,000 after purchasing an additional 86,249 shares during the last quarter. Leisure Capital Management purchased a new position in shares of BioCryst Pharmaceuticals in the second quarter valued at $173,000. Finally, Panagora Asset Management Inc. raised its stake in shares of BioCryst Pharmaceuticals by 2.8% during the 2nd quarter. Panagora Asset Management Inc. now owns 650,318 shares of the biotechnology company’s stock worth $4,019,000 after buying an additional 17,759 shares during the last quarter. Institutional investors and hedge funds own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Stock Performance

Shares of NASDAQ BCRX opened at $7.53 on Friday. BioCryst Pharmaceuticals, Inc. has a 1 year low of $4.03 and a 1 year high of $8.88. The stock’s 50-day simple moving average is $7.61 and its 200-day simple moving average is $7.39. The firm has a market cap of $1.56 billion, a price-to-earnings ratio of -12.34 and a beta of 1.79.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share for the quarter, meeting the consensus estimate of ($0.07). The firm had revenue of $117.10 million during the quarter, compared to the consensus estimate of $113.99 million. The firm’s quarterly revenue was up 35.1% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.19) earnings per share. As a group, research analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.38 EPS for the current year.

Wall Street Analyst Weigh In

BCRX has been the topic of several recent research reports. Barclays upped their price target on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an “equal weight” rating in a report on Tuesday, November 5th. Needham & Company LLC reaffirmed a “buy” rating and issued a $14.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $10.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 5th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $15.60.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.